Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells

Charn Jung Chang, Chih Hung Chiang, Wen Shin Song, Shen Kou Tsai, Lin Chung Woung, Chin Hong Chang, Shaw Yeu Jeng, Ching Yao Tsai, Chuan Chih Hsu, Hung Fu Lee, Chi Shuan Huang, Ming Chi Yung, Jorn Hon Liu, Kai Hsi Lu

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Introduction: CD133 (PROM1) is a potential marker for cancer stem cells (CSCs), including those found in brain tumors. Recently, medulloblastoma (MB)-derived CD133-positive cells were found to have CSC-like properties and were proposed to be important contributors to tumorigenicity, cancer progression, and chemoradioresistance. However, the biomolecular pathways and therapeutic targets specific to MB-derived CSCs remain unresolved. Materials and methods: In the present study, we isolated CD133+ cells from MB cell lines and determined that they showed increased tumorigenicity, radioresistance, and higher expression of both embryonic stem cell-related and drug resistance-related genes compared to CD133- cells. Bioinformatics analysis suggested that the STAT3 pathway might be important in MB and CD133+ cells. To evaluate the effects of inhibiting the STAT3 pathway, MB-derived CD133+/- cells were treated with the potent STAT3 inhibitor, cucurbitacin I. Treatment with cucurbitacin I significantly suppressed the CSC-like properties and stemness gene signature of MB-derived CD133+ cells. Furthermore, cucurbitacin I treatment increased the apoptotic sensitivity of MB-derived CD133+ cells to radiation and chemotherapeutic drugs. Notably, cucurbitacin I demonstrated synergistic effects with ionizing radiation to inhibit tumorigenicity in MB-CD133 +-inoculated mice. Results: These results indicate that the STAT3 pathway plays a key role in mediating CSC properties in MB-derived CD133 + cells. Targeting STAT3 with cucurbitacin I may therefore represent a novel therapeutic approach for treating malignant brain tumors.

Original languageEnglish
Pages (from-to)363-373
Number of pages11
JournalChild's Nervous System
Volume28
Issue number3
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Medulloblastoma
Neoplastic Stem Cells
Brain Neoplasms
cucurbitacin I
Embryonic Stem Cells
Ionizing Radiation
Computational Biology
Drug Resistance
Genes
Radiation
Cell Line

Keywords

  • Cancer stem cells
  • CD133
  • Cucurbitacin I
  • Medulloblastoma
  • Radioresistance
  • STAT3

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology
  • Medicine(all)

Cite this

Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells. / Chang, Charn Jung; Chiang, Chih Hung; Song, Wen Shin; Tsai, Shen Kou; Woung, Lin Chung; Chang, Chin Hong; Jeng, Shaw Yeu; Tsai, Ching Yao; Hsu, Chuan Chih; Lee, Hung Fu; Huang, Chi Shuan; Yung, Ming Chi; Liu, Jorn Hon; Lu, Kai Hsi.

In: Child's Nervous System, Vol. 28, No. 3, 2012, p. 363-373.

Research output: Contribution to journalArticle

Chang, CJ, Chiang, CH, Song, WS, Tsai, SK, Woung, LC, Chang, CH, Jeng, SY, Tsai, CY, Hsu, CC, Lee, HF, Huang, CS, Yung, MC, Liu, JH & Lu, KH 2012, 'Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells', Child's Nervous System, vol. 28, no. 3, pp. 363-373. https://doi.org/10.1007/s00381-011-1672-x
Chang, Charn Jung ; Chiang, Chih Hung ; Song, Wen Shin ; Tsai, Shen Kou ; Woung, Lin Chung ; Chang, Chin Hong ; Jeng, Shaw Yeu ; Tsai, Ching Yao ; Hsu, Chuan Chih ; Lee, Hung Fu ; Huang, Chi Shuan ; Yung, Ming Chi ; Liu, Jorn Hon ; Lu, Kai Hsi. / Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells. In: Child's Nervous System. 2012 ; Vol. 28, No. 3. pp. 363-373.
@article{4fd48814ae5f46958bf879fea6b5bacf,
title = "Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells",
abstract = "Introduction: CD133 (PROM1) is a potential marker for cancer stem cells (CSCs), including those found in brain tumors. Recently, medulloblastoma (MB)-derived CD133-positive cells were found to have CSC-like properties and were proposed to be important contributors to tumorigenicity, cancer progression, and chemoradioresistance. However, the biomolecular pathways and therapeutic targets specific to MB-derived CSCs remain unresolved. Materials and methods: In the present study, we isolated CD133+ cells from MB cell lines and determined that they showed increased tumorigenicity, radioresistance, and higher expression of both embryonic stem cell-related and drug resistance-related genes compared to CD133- cells. Bioinformatics analysis suggested that the STAT3 pathway might be important in MB and CD133+ cells. To evaluate the effects of inhibiting the STAT3 pathway, MB-derived CD133+/- cells were treated with the potent STAT3 inhibitor, cucurbitacin I. Treatment with cucurbitacin I significantly suppressed the CSC-like properties and stemness gene signature of MB-derived CD133+ cells. Furthermore, cucurbitacin I treatment increased the apoptotic sensitivity of MB-derived CD133+ cells to radiation and chemotherapeutic drugs. Notably, cucurbitacin I demonstrated synergistic effects with ionizing radiation to inhibit tumorigenicity in MB-CD133 +-inoculated mice. Results: These results indicate that the STAT3 pathway plays a key role in mediating CSC properties in MB-derived CD133 + cells. Targeting STAT3 with cucurbitacin I may therefore represent a novel therapeutic approach for treating malignant brain tumors.",
keywords = "Cancer stem cells, CD133, Cucurbitacin I, Medulloblastoma, Radioresistance, STAT3",
author = "Chang, {Charn Jung} and Chiang, {Chih Hung} and Song, {Wen Shin} and Tsai, {Shen Kou} and Woung, {Lin Chung} and Chang, {Chin Hong} and Jeng, {Shaw Yeu} and Tsai, {Ching Yao} and Hsu, {Chuan Chih} and Lee, {Hung Fu} and Huang, {Chi Shuan} and Yung, {Ming Chi} and Liu, {Jorn Hon} and Lu, {Kai Hsi}",
year = "2012",
doi = "10.1007/s00381-011-1672-x",
language = "English",
volume = "28",
pages = "363--373",
journal = "Child's Nervous System",
issn = "0256-7040",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells

AU - Chang, Charn Jung

AU - Chiang, Chih Hung

AU - Song, Wen Shin

AU - Tsai, Shen Kou

AU - Woung, Lin Chung

AU - Chang, Chin Hong

AU - Jeng, Shaw Yeu

AU - Tsai, Ching Yao

AU - Hsu, Chuan Chih

AU - Lee, Hung Fu

AU - Huang, Chi Shuan

AU - Yung, Ming Chi

AU - Liu, Jorn Hon

AU - Lu, Kai Hsi

PY - 2012

Y1 - 2012

N2 - Introduction: CD133 (PROM1) is a potential marker for cancer stem cells (CSCs), including those found in brain tumors. Recently, medulloblastoma (MB)-derived CD133-positive cells were found to have CSC-like properties and were proposed to be important contributors to tumorigenicity, cancer progression, and chemoradioresistance. However, the biomolecular pathways and therapeutic targets specific to MB-derived CSCs remain unresolved. Materials and methods: In the present study, we isolated CD133+ cells from MB cell lines and determined that they showed increased tumorigenicity, radioresistance, and higher expression of both embryonic stem cell-related and drug resistance-related genes compared to CD133- cells. Bioinformatics analysis suggested that the STAT3 pathway might be important in MB and CD133+ cells. To evaluate the effects of inhibiting the STAT3 pathway, MB-derived CD133+/- cells were treated with the potent STAT3 inhibitor, cucurbitacin I. Treatment with cucurbitacin I significantly suppressed the CSC-like properties and stemness gene signature of MB-derived CD133+ cells. Furthermore, cucurbitacin I treatment increased the apoptotic sensitivity of MB-derived CD133+ cells to radiation and chemotherapeutic drugs. Notably, cucurbitacin I demonstrated synergistic effects with ionizing radiation to inhibit tumorigenicity in MB-CD133 +-inoculated mice. Results: These results indicate that the STAT3 pathway plays a key role in mediating CSC properties in MB-derived CD133 + cells. Targeting STAT3 with cucurbitacin I may therefore represent a novel therapeutic approach for treating malignant brain tumors.

AB - Introduction: CD133 (PROM1) is a potential marker for cancer stem cells (CSCs), including those found in brain tumors. Recently, medulloblastoma (MB)-derived CD133-positive cells were found to have CSC-like properties and were proposed to be important contributors to tumorigenicity, cancer progression, and chemoradioresistance. However, the biomolecular pathways and therapeutic targets specific to MB-derived CSCs remain unresolved. Materials and methods: In the present study, we isolated CD133+ cells from MB cell lines and determined that they showed increased tumorigenicity, radioresistance, and higher expression of both embryonic stem cell-related and drug resistance-related genes compared to CD133- cells. Bioinformatics analysis suggested that the STAT3 pathway might be important in MB and CD133+ cells. To evaluate the effects of inhibiting the STAT3 pathway, MB-derived CD133+/- cells were treated with the potent STAT3 inhibitor, cucurbitacin I. Treatment with cucurbitacin I significantly suppressed the CSC-like properties and stemness gene signature of MB-derived CD133+ cells. Furthermore, cucurbitacin I treatment increased the apoptotic sensitivity of MB-derived CD133+ cells to radiation and chemotherapeutic drugs. Notably, cucurbitacin I demonstrated synergistic effects with ionizing radiation to inhibit tumorigenicity in MB-CD133 +-inoculated mice. Results: These results indicate that the STAT3 pathway plays a key role in mediating CSC properties in MB-derived CD133 + cells. Targeting STAT3 with cucurbitacin I may therefore represent a novel therapeutic approach for treating malignant brain tumors.

KW - Cancer stem cells

KW - CD133

KW - Cucurbitacin I

KW - Medulloblastoma

KW - Radioresistance

KW - STAT3

UR - http://www.scopus.com/inward/record.url?scp=84860855712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860855712&partnerID=8YFLogxK

U2 - 10.1007/s00381-011-1672-x

DO - 10.1007/s00381-011-1672-x

M3 - Article

C2 - 22249380

AN - SCOPUS:84860855712

VL - 28

SP - 363

EP - 373

JO - Child's Nervous System

JF - Child's Nervous System

SN - 0256-7040

IS - 3

ER -